Telios Pharmaceuticals
Executive Summary
Ono Pharmaceutical Co. Ltd. (Osaka) acquires "significant equity investment" and is supplying "several million dollars" to privately held San Diego-based R&D firm to develop Transforming Growth Factor-beta-based drugs. Ono will fund R&D and clinical testing of TGFb drugs that block "abnormal tissue scarring involved in kidney inflammation, pulmonary fibrosis, liver cirrhosis and other fibrotic disorders" in return for marketing rights in Japan, Taiwan and South Korea. Telios retains rights elsewhere. Agreement also gives Ono first right of refusal in the same countries for all other Telios human drug products -- excluding firm's blood-clot inhibitors and (ITALICS)Telio-derm(END ITALICS) wound healing gel ("The Pink Sheet" Aug. 13, T&G-9). Ono already has Asian license for Telios' "dry eye" product (ITALICS)Oculos,(END ITALICS) which is in development.
You may also be interested in...
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: